Date: 2017-08-10
Type of information: Nomination
Compound: president and chief executive officer
Company: Orchard Therapeutics (UK)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On August 10, 2017, Orchard Therapeutics announcec the appointment of Mark Rothera as president and chief executive officer. Mark Rothera brings 28 years of experience in the biopharmaceutical industry including driving the transition of multiple emerging biotechnology companies from R&D stage to commercialisation. During his career, he has focused on bringing novel therapies to market for patients with rare diseases, and has launched seven orphan drugs. Until recently he served as chief commercial officer of PTC Therapeutics where he helped transition the company from a privately funded, US-based R&D biotech to a public, commercial stage company with a 47 country commercialisation footprint. Prior to joining PTC, he served as Global President of Aegerion Pharmaceuticals and Vice President and General Manager of commercial operations at Shire Human Genetic Therapies for Europe, Middle East and Africa. He received an M.A. in Natural Sciences from Cambridge University and an MBA from INSEAD.
Financial terms:
Latest news:
Is general: Yes
